Evidence map›Paper›PMID 18697213›Full record

ArticleHepatology (Baltimore, Md.)2008

Specific targeting of hepatitis C virus core protein by an intracellular single-chain antibody of human origin.

Juliane Karthe, Kathi Tessmann, Jisu Li, Raiki Machida, Maaike Daleman, Dieter Häussinger, Tobias Heintges

Abstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Juliane KartheDepartment of Gastroenterology, Hepatology and Infectious Diseases, Heinrich-Heine-University, Düsseldorf, Germany.
Kathi Tessmann
Jisu Li
Raiki Machida
Maaike Daleman
Dieter Häussinger
Tobias Heintges
Heinrich Heine University Düsseldorf · DERhode Island Hospital · USBrown University · US

Funding

Molecular Target(s) for Interruption of HBV InfectionR01CA109733 · NCI · RHODE ISLAND HOSPITAL · PI LI, JISU · 2005 to 2009
$1.1M
Hepatitis C virus core protein and cell proliferationR21DK066950 · NIDDK · RHODE ISLAND HOSPITAL · PI LI, JISU · 2004 to 2005
$308k
NCI NIH HHS CA109733NCI NIH HHS R01 CA109733NIDDK NIH HHS DK066950NIDDK NIH HHS R21 DK066950
6 · The paper itself

Abstract

The hepatitis C virus (HCV) core protein is essential for viral genome encapsidation and plays an important role in steatosis, immune evasion, and hepatocellular carcinoma. It may thus represent a promising therapeutic target to interfere with the HCV life-cycle and related pathogenesis. In this study, we used phage display to generate single-chain variable domain antibody fragments (scFv) to the core protein from bone marrow plasma cells of patients with chronic hepatitis C. An antibody with high-affinity binding (scFv42C) was thus identified, and the binding site was mapped to the PLXG motif (residues 84-87) of the core protein conserved among different genotypes. Whereas scFv42C displayed diffuse cytoplasmic fluorescence when expressed alone in the Huh7 human hepatoma cell line, cotransfection with the core gene shifted its subcellular distribution into that of core protein. The intracellular association of scFv42C with its target core protein was independently demonstrated by the fluorescence resonance energy transfer technique. Interestingly, expression of the single-chain antibody reduced core protein levels intracellularly, particularly in the context of full HCV replication. Moreover, cell proliferation as induced by the core protein could be reversed by scFv4C coexpression. Therefore, scFv42C may represent a novel anti-HCV agent, which acts by sequestering core protein and attenuating core protein-mediated pathogenesis.

Indexed as

HepacivirusAmino Acid SequenceAntibodies, ViralAntiviral AgentsCarcinoma, HepatocellularCell Line, TumorCell ProliferationFluorescence Resonance Energy TransferHepatitis C, ChronicHumansImmunoglobulin FragmentsLiverLiver NeoplasmsMolecular Sequence DataProtein Interaction Domains and MotifsViral Core ProteinsAntibodies, ViralAntiviral AgentsImmunoglobulin FragmentsViral Core Proteins

Identifiers

PMID18697213
PMCPMC3080105
OpenAlexW2083745456

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.